Coagulation assessment with the new generation of oral anticoagulants

Emergency Medicine Journal

Volumn 33, Issue 6, 2016, Pages 423-430

  Pollack, Charles V ^a  

^a PENNSYLVANIA HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; APIXABAN; DABIGATRAN ETEXILATE; RIVAROXABAN; WARFARIN;

ANTICOAGULANT THERAPY; ANTICOAGULATION; BLOOD CLOTTING TEST; CLINICAL PROTOCOL; DRUG SCREENING; DRUG USE; EMERGENCY WARD; HUMAN; INTERNATIONAL NORMALIZED RATIO; PATIENT CARE; PHYSICIAN; PRIORITY JOURNAL; REVIEW; BLOOD CLOTTING; HOSPITAL EMERGENCY SERVICE; ORAL DRUG ADMINISTRATION; THROMBOEMBOLISM; THROMBOSIS;

ADMINISTRATION, ORAL; ANTICOAGULANTS; BLOOD COAGULATION; EMERGENCY SERVICE, HOSPITAL; HUMANS; INTERNATIONAL NORMALIZED RATIO; THROMBOEMBOLISM; THROMBOSIS; WARFARIN;

EID: 84969567323     PISSN: 14720205     EISSN: 14720213     Source Type: Journal    
DOI: 10.1136/emermed-2015-204891     Document Type: Review

References (80)

1. Holbrook A, Schulman S, Witt DM, et al. Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141(2 Suppl):e152S-84S.
2. Hylek EM, Go AS, Chang Y, et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med 2003;349:1019-26.
3. Garcia DA, Baglin TP, Weitz JI, et al. Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141(2 Suppl): e24S-43S.
4. Ageno W, Gallus AS, Wittkowsky A, et al. Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141 (2 Suppl):e44S-88S.
5. Wysowski DK, Nourjah P, Swartz L. Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action. Arch Intern Med 2007;167:1414-19.
6. You JJ, Singer DE, Howard PA, et al. Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141(2 Suppl):e531S-75S.
7. Fuster V, Rydén LE, Cannom DS, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006;114:e257-354.
8. Hylek EM, Singer DE. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med 1994;120:897-902.
9. Connolly SJ, Pogue J, Eikelboom J, et al. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation 2008;118:2029-37.
10. Pirmohamed M, James S, Meakin S, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 2004;329:15-19.
11. Budnitz DS, Lovegrove MC, Shehab N, et al. Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med 2011;365:2002-12.
12. Anthony CJ, Karim S, Ackroyd-Stolarz S, et al. Intensity of anticoagulation with warfarin and risk of adverse events in patients presenting to the emergency department. Ann Pharmacother 2011;45:881-7.
13. Meeker E, Dennehy CE, Weber EJ, et al. Emergency department management of patients on warfarin therapy. Ann Emerg Med 2011;58:192-9.
14. Kirley K, Qato DM, Kornfield R, et al. National trends in oral anticoagulant use in the United States, 2007 to 2011. Circ Cardiovasc Qual Outcomes 2012;5:615-21.
15. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-51.
16. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Newly identified events in the RE-LY trial. N Engl J Med 2010;363:1875-6.
17. Boehringer Ingelheim Pharmaceuticals I. Pradaxa prescribing information. Boehringer Ingelheim Pharmaceuticals, Inc., 2015:1-16.
18. Janssen Pharmaceuticals I. Xarelto prescribing information. Titusville, NJ: Janssen Pharmaceuticals, Inc., 2014:1-13.
19. Bristol-Meyers Squibb I. Eliquis prescribing information. Bristol-Meyers Squibb Company, 2014:1-30.
20. Yamashita T, Koretsune Y, Yasaka M, et al. Randomized, multicenter, warfarin-controlled phase II study of edoxaban in Japanese patients with non-valvular atrial fibrillation. Circ J 2012;76:1840-7.
21. Daiichi Sankyo I. Savaysa prescribing information. Parsippany, NJ, USA: Daiichi Sankyo, Inc., 2015:32.
22. Stangier J, Rathgen K, Stähle H, et al. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 2007;64:292-303.
23. Boehringer Ingelheim Pharmaceuticals Inc. Highlights of prescribing information. Pradaxa (dabigatran etexilate mesylate) capsules for oral use. Ridgefield, CT, USA: Boehringer Ingelheim Pharmaceuticals, Inc., December 2012. 2014. (updated last updated April 2014 accessed 21 April 2014). http://bidocs.boehringer-ingelheim. com/BIWebAccess/ViewServlet.ser?docBase=renetnt&folderPath=/Prescribing% 20Information/PIs/Pradaxa/Pradaxa.pdf
24. van Ryn J, Stangier J, Haertter S, et al. Dabigatran etexilate-a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010;103:1116-27.
25. van Ryn J, Baruch L, Clemens A. Interpretation of point-of-care INR results in patients treated with dabigatran. Am J Med 2012;125:417-20.
26. Lindahl TL, Baghaei F, Blixter IF, et al. Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays. Thromb Haemost 2011;105:371-8.
27. Baruch L, Sherman O. Potential inaccuracy of point-of-care INR in dabigatran-treated patients. Ann Pharmacother 2011;45:e40.
28. Hillarp A, Baghaei F, Fagerberg Blixter I, et al. Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays. J Thromb Haemost 2011;9:133-9.
29. Janssen Pharmaceuticals Inc. Highlights of prescribing information. Xarelto (rivaroxaban) tablets for oral use. Janssen Pharmaceuticals, 2011. http://www.xareltohcp.com/sites/default/files/shared/xarelto-0.pdf#zoom=100 (accessed 21 Apr 2014).
30. Samama MM, Martinoli JL, LeFlem L, et al. Assessment of laboratory assays to measure rivaroxaban-an oral, direct factor Xa inhibitor. Thromb Haemost 2010;103:815-25.
31. Kubitza D, Becka M, Wensing G, et al. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939-an oral, direct factor Xa inhibitor-after multiple dosing in healthy male subjects. Eur J Clin Pharmacol 2005;61:873-80.
32. Hirsh J, Fuster V, Ansell J, et al. American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. Circulation 2003;107:1692-711.
33. Poller L. International normalized ratios (INR): the first 20 years. J Thromb Haemost 2004;2:849-60.
34. Marlar RA, Cook J, Johnston M, et al. One-stage prothrombin time (PT) test and activated partial thromboplastin time (APTT) test; approved guideline. 2nd edn. Wayne, PA: Clinical and Laboratory Standards Institute, 2008. http://shopping. netsuite.com/c.1253739/site/Sample-pdf/H47-A2.pdf
35. Garcia D, Ageno W, Bussey H, et al. Prevention and treatment of bleeding complications in patients receiving vitamin K antagonists, part 1: prevention. Am J Hematol 2009;84:579-83.
36. Holbrook AM, Pereira JA, Labiris R, et al. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med 2005;165:1095-106.
37. Hylek EM, Heiman H, Skates SJ, et al. Acetaminophen and other risk factors for excessive warfarin anticoagulation. JAMA 1998;279:657-62.
38. Meegaard PM, Holck LH, Pottegard A, et al. Excessive anticoagulation with warfarin or phenprocoumon may have multiple causes. Dan Med J 2012;59:A4383.
39. Panneerselvam S, Baglin C, Lefort W, et al. Analysis of risk factors for over-anticoagulation in patients receiving long-term warfarin. Br J Haematol 1998;103:422-4.
40. Adcock DM, Kressin DC, Marlar RA. Minimum specimen volume requirements for routine coagulation testing: dependence on citrate concentration. Am J Clin Pathol 1998;109:595-9.
41. Raghavan N, Frost CE, Yu Z, et al. Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos 2009;37:74-81.
42. Bristol-Myers Squibb Company and Pfizer Inc. Highlights of prescribing information. Eliquis (apixaban) tablets for oral use. 2012. http://packageinserts.bms.com/pi/pi- eliquis.pdf (accessed 21 Apr 2014).
43. Frost C, Wang J, Nepal S, et al. Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects. Br J Clin Pharmacol 2013;75:476-87.
44. Barrett YC, Wang Z, Frost C, et al. Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay. Thromb Haemost 2010;104:1263-71.
45. Douxfils J, Mullier F, Robert S, et al. Impact of dabigatran on a large panel of routine or specific coagulation assays Laboratory recommendations for monitoring of dabigatran etexilate. Thromb Haemost 2012;107:985-97.
46. Stangier J, Feuring M. Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran. Blood Coagul Fibrinolysis 2012;23:138-43.
47. Avecilla ST, Ferrell C, Chandler WL, et al. Plasma-diluted thrombin time to measure dabigatran concentrations during dabigatran etexilate therapy. Am J Clin Pathol 2012;137:572-4.
48. Samama MM, Guinet C, Le Flem L, et al. Measurement of dabigatran and rivaroxaban in primary prevention of venous thromboembolism in 106 patients, who have undergone major orthopedic surgery: an observational study. J Thromb Thrombolysis 2013;35:140-6.
49. Samama MM, Amiral J, Guinet C, et al. An optimised, rapid chromogenic assay, specific for measuring direct factor Xa inhibitors (rivaroxaban) in plasma. Thromb Haemost 2010;104:1078-9.
50. Tripodi A, Chantarangkul V, Guinet C, et al. The international normalized ratio calibrated for rivaroxaban has the potential to normalize prothrombin time results for rivaroxaban-treated patients: results of an in vitro study. J Thromb Haemost 2011;9:226-8.
51. Tripodi A. Which test to use to measure the anticoagulant effect of rivaroxaban: the prothrombin time test. J Thromb Haemost 2013;11:576-8.
52. Samama MM. Which test to use to measure the anticoagulant effect of rivaroxaban: the anti-factor Xa assay. J Thromb Haemost 2013;11:579-80.
53. Becker RC, Yang H, Barrett Y, et al. Chromogenic laboratory assays to measure the factor Xa-inhibiting properties of apixaban-an oral, direct and selective factor Xa inhibitor. J Thromb Thrombolysis 2011;32:183-7.
54. Barrett YC, Wang J, Song Y, et al. A randomised assessment of the pharmacokinetic, pharmacodynamic and safety interaction between apixaban and enoxaparin in healthy subjects. Thromb Haemost 2012;107:916-24.
55. Liesenfeld KH, Lehr T, Dansirikul C, et al. Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial. J Thromb Haemost 2011;9:2168-75.
56. Boehringer Ingelheim Pharmaceuticals Inc. Advisory committee briefing document: dabigatran etexilate. 2010. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterialsDrugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM226009.pdf (accessed 21 Apr 2014).
57. Ezekowitz MD, Reilly PA, Nehmiz G, et al. Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study). Am J Cardiol 2007;100:1419-26.
58. Stangier J, Rathgen K, Stähle H, et al. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin Pharmacokinet 2010;49:259-68.
59. Richter KC. TAS Ecarin clotting time test. Administration FaD, 2000.
60. Garcia DA, Regan S, Crowther M, et al. The risk of hemorrhage among patients with warfarin-associated coagulopathy. J Am Coll Cardiol 2006;47:804-8.
61. Ageno W, Garcia D, Aguilar MI, et al. Prevention and treatment of bleeding complications in patients receiving vitamin K antagonists, part 2: treatment. Am J Hematol 2009;84:584-8.
62. Morgenstern LB, Hemphill JC III, Anderson C, Jr, et al. Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2010;41:2108-29.
63. van Ryn J, Litzenburger T, Schurer J. Reversal of anticoagulant activity of dabigatran and dabigatran-induced bleeding in rats by a specific antidote (antibody fragment) [abstract]. Circulation 2012;126(21 Suppl):A9928.
64. Hutchaleelaha A, Lu G, Deguzman FR, et al. Recombinant factor Xa inhibitor antidote (PRT064445) mediates reversal of anticoagulation through reduction of free drug concentration: a common mechanism for direct factor Xa inhibitors. Eur Heart J 2012;33(Suppl 1):496.
65. Levi M, Moore KT, Castillejos CF, et al. Comparison of three-factor and four-factor prothrombin complex concentrates regarding reversal of the anticoagulant effects of rivaroxaban in healthy volunteers. J Thromb Haemost 2014;12:1428-36.
66. Khadzhynov D, Wagner F, Formella S, et al. Effective elimination of dabigatran by haemodialysis. A phase I single-centre study in patients with end-stage renal disease. Thromb Haemost 2013;109:596-605.
67. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883-91.
68. Al-Khatib SM, Thomas L, Wallentin L, et al. Outcomes of apixaban vs. warfarin by type and duration of atrial fibrillation: results from the ARISTOTLE trial. Eur Heart J 2013;34:2464-71.
69. Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013;369:2093-104.
70. Schiele F, van Ryn J, Canada K, et al. A specific antidote for dabigatran: functional and structural characterization. Blood 2013;121:3554-62.
71. Boehringer Ingelheim GmbH. Boehringer Ingelheim's Investigational Antidote for Pradaxa (dabigatran etexilate mesylate) Receives FDA Breakthrough Therapy Designation. Ridgefield, CT: Boehringer Ingelheim GmbH, 2014. (updated 26 June 2014; cited 12 August 2014; Press release). http://us.boehringer-ingelheim.com/news-events/press-releases/press-release-archive/2014/06-26-14-boehringeringelheim-investigational-antidote-pradaxa-dabigatran-etexilate-mesylate-fdabreakthrough-therapy-designation.html
72. Vandana M, Michael K, Genmin L, et al, eds. A phase 2 randomized, double-blind, placebo-controlled trial demonstrating reversal of rivaroxaban-induced anticoagulation in healthy subjects by andexanet alfa (PRT064445), an antidote for Fxa inhibitors. Presented at: 55th American Society of Hematology Annual Meeting and Exposition; Abstract 3636 7-10 December 2013; New Orleans: Louisiana.
73. Portola Pharmaceuticals I. Portola Pharmaceuticals Receives Breakthrough Therapy Designation From FDA for Andexanet Alfa (PRT4445), Investigational Factor Xa Inhibitor Antidote. [Webpage] 2013. http://investors.portola.com/phoenix.zhtml?c=198136&p=irol-newsArticle&ID=1879666 (cited 22 Sept 2014).
74. Kubitza D, Becka M, Mueck W, et al. Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct factor Xa inhibitor. Br J Clin Pharmacol 2010;70:703-12.
75. Eikelboom JW, Connolly SJ, Gao P, et al. Stroke risk and efficacy of apixaban in atrial fibrillation patients with moderate chronic kidney disease. J Stroke Cerebrovasc Dis 2012;21:429-35.
76. Hohnloser SH, Hijazi Z, Thomas L, et al. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J 2012;33:2821-30.
77. Kaatz S, Kouides PA, Garcia DA, et al. Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. Am J Hematol 2012;87(Suppl 1):S141-5.
78. Glund S, Stangier J, Schmohl M, et al. A specific antidote for dabigatran: Immediate, complete and sustained reversal of dabigatran induced anticoagulation in healthy male volunteers. Presented at: American Heart Association Scientific Sessions 2013; November 17-19, 2013; Dallas, Texas2013.
79. Portola Pharmaceuticals I. Andexanet alfa: FXa Inhibitor Antidote. [Webpage]. 2014. (updated 2014; cited 14 Aug 2014). http://www.portola.com/clinicaldevelopment/andexanet-alfa-prt4445-fxa-inhibitor-antidote/
80. Morishima Y, Kamisato C. Laboratory measurements of the oral direct factor Xa inhibitor edoxaban: comparison of prothrombin time, activated partial thromboplastin time, and thrombin generation assay. Am J Clin Pathol 2015;143:241-7.